HRTX - Heron Therapeuti logo

HRTX

Heron Therapeuti

Heron Therapeutics develops therapies using its Biochronomer drug delivery technology for effective management of chemotherapy-related nausea and postoperative nausea. Key products include SUSTOL, CINVANTI, ZYNRELEF, and APONVIE, targeting cancer patients and surgical recovery.

โš•๏ธ Healthcare NASDAQ Listed 1987 $ USD
$1,000 invested 30 years ago โ†’$1today

Score Overview

1 Year
Score
Net Growth-68.60%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growth-2.41%
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Score6.2
Net Growth84.36%
Net Trend60%
Net Income Consistencyโ€”
Rev Growth75.08%
Rev Trend80%
Revenue Consistencyโ€”
10 Years
Score
Net Growth80.33%
Net Trend50%
Net Income Consistency
Rev Growth118x
Rev Trend70%
Revenue Consistency
20 Years
Score2.9
Net Growth-6x
Net Trend35%
Net Income Consistency
Rev Growth28x
Rev Trend55%
Revenue Consistency
30 Years
Score
Net Growth-262.22%
Net Trend40%
Net Income Consistency
Rev Growth8x
Rev Trend53%
Revenue Consistency
All Time
Score
Net Growth-6x
Net Trend41%
Net Income Consistency
Rev Growth88x
Rev Trend59%
Revenue Consistency

See the full market ranking โ†’

Heron Therapeuti fundamental performance

Between 2020 and 2025, revenue grew from $ 88M to $ 154M and net income went from -$ 224M to -$ 20M. Revenue increased in 4 of those 5 years; net income in 3.

Between 2015 and 2025, revenue grew from $ 0.00 to $ 154M and net income went from -$ 97M to -$ 20M. Revenue increased in 7 of those 10 years; net income in 5.

Heron Therapeuti currently holds a 20-year HDB Score of 2.9 out of 10. How the HDB Score is calculated.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 0.34โ€”
1 Year2025-08-12
$ 1.31-73.98%
5 Years2021-08-12
$ 11.32-96.99%
10 Years2016-08-12
$ 20.41-98.33%
20 Years2006-08-11
$ 71.20-99.52%
30 Years1996-08-12
$ 590.00-99.94%
All Time1987-08-26
$ 580.00-99.94%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 151M-$ 34M$ 42M
2025$ 154M-$ 20M$ 46M
2024$ 144M-$ 13M$ 59M
2023$ 127M-$ 110M$ 80M
2022$ 107M-$ 134M$ 84M
2021$ 86M-$ 217M$ 157M
2020$ 88M-$ 224M$ 208M
2019$ 145M-$ 204M$ 390M
2018$ 77M-$ 178M$ 332M
2017$ 30M-$ 197M$ 172M
2016$ 1M-$ 173M$ 51M
2015$ 0.00-$ 97M$ 131M
2014$ 0.00-$ 76M$ 72M
2013$ 0.00-$ 55M$ 72M
2012-$ 599K-$ 23M$ 53M
2011$ 646K-$ 11M$ 17M
2010$ 1M-$ 7M$ 2M
2009$ 1M-$ 10M$ 7M
2008$ 369K-$ 23M$ 10M
2007$ 412K-$ 20M$ 35M
2006$ 5M$ 5M$ 15M
2005$ 5M-$ 8M$ 5M
2004$ 5M-$ 9M$ 13M
2003$ 4M-$ 4M$ 9M
2002$ 5M-$ 3M$ 14M
2001$ 4M-$ 2M$ 19M
2000$ 3M$ 8M$ 22M
1999$ 20M-$ 2M$ 3M
1998$ 20M-$ 2M$ 4M
1997$ 17M-$ 1M$ 8M
1996$ 18M-$ 9M$ 5M
1995$ 16M-$ 9M$ 5M
1994$ 15M-$ 9M$ 2M
1993$ 19M-$ 9M$ 1M
1992$ 7M-$ 5M$ 2M
1991$ 2M-$ 4M$ 1M
1990$ 2M-$ 3M$ 1M
1989$ 2M-$ 4M$ 2M
1988$ 2M-$ 5M$ 11M
IPO1987$ 1M-$ 3M$ 15M

Explore beyond HRTX

You're looking at Heron Therapeuti. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies